-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
In recent years, proprietary Chinese medicines for colds have become a very popular category in the traditional Chinese medicine market of physical pharmacies
.
Statistics show that the current sales of physical pharmacies in Chinese cities have exceeded 10 billion yuan
.
With the continuous expansion of the market, many pharmaceutical companies have also begun to innovate in traditional Chinese medicine for colds
.
Among them, it is worth mentioning that in the field of Chinese patent medicines for colds recently, the approval of Class 1 innovative drugs has been launched
.
On November 15, Kangyuan Pharmaceutical issued an announcement stating that the company’s Yinqiao Qingre Tablets were approved by the State Food and Drug Administration to be used for the treatment of exogenous wind-heat common colds
.
Public information shows that the prescription of Yinqiao Qingre Tablets is based on the famous prescription "Yinqiao Baidu Decoction" of febrile disease by Professor Wang Yongyan, an academician of the Chinese Academy of Engineering.
, Published to relieve muscle, and has the therapeutic effects of clearing lung heat, relieving throat and pain, purging fire and detoxification, relieving cough and resolving phlegm
.
In addition, it is understood that Kangyuan Pharmaceutical’s Yinqiao Qingre Tablets are not only the first category 1.
1 Chinese medicine innovative drug approved for marketing since the implementation of the new Chinese medicine registration classification on July 1, 2020, but also the approval of Jinhua Qinggan Granules in 2016.
Later, in the past five years, it was the first innovative Chinese medicine for colds to be approved for marketing
.
In this regard, the industry believes that the listing of the drug will have an important impact on the market structure of tens of billions of cold Chinese patent medicines, and will further intensify the competition of pharmaceutical companies in this market
.
It is understood that the competition in the cold medicine market of Zhongcheng has been fierce
.
For example, China Resources Sanjiu, Yiling Pharmaceutical, Harbin Medicine Sanjing Pharmaceutical, Henan Tailong Pharmaceutical, Guangzhou Xiangxue Pharmaceutical, etc.
have been increasing their market share in the cold medicine market in recent years
.
Among them, it is worth noting that from the perspective of the market pattern of Chinese patent medicine cold medicines in Chinese urban retail pharmacies in 2020, among the top 20 manufacturers of Chinese patent medicine cold medicines, the position of the “big brother” of China Resources Sanjiu Medicine has been very stable.
It is expected that The market share accounted for 20.
83%
.
The analysis believes that the reason for this phenomenon is mainly due to the rich product line of China Resources Sanjiu Cold and Fever.
Related varieties such as Sanjiu Chinese Medicine Formula Granules, 999 Ganmaoling, 999 Banlangen Granules, 999 Ganmao Qingre Granules, 999 Children’s Cold Medicine and other market demand The amount is also relatively large
.
In addition to China Resources Sanjiu, Shijiazhuang Yiling Pharmaceutical's share in the cold medicine market has also increased significantly in recent years
.
Especially when the epidemic was raging in the first half of 2020, the National Health Commission included Lianhua Qingwen Capsules into the diagnosis and treatment plan.
For a time, Lianhua Qingwen Capsules were swept away in major online and offline pharmacies
.
As a result, the sales volume of Lianhua Qingwen Capsules will greatly increase in 2020.
In the first half of 2020, Lianhua Qingwen accounted for 53% of CR5 cold medicines, and 37.
94% of the overall market of Chinese patent cold medicines
.
It is worth noting that, in addition to a large number of cold Chinese patent medicines that are currently on the market, there are two other cold Chinese patent medicines that are under review, including Shenzhen Sanshun Pharmaceutical’s Caohong Capsules and Tasly’s Xiao Chaihu Decoction Drops.
Pill
.
In this regard, the industry predicts that under the background of the emergence of new drugs, the market for tens of billions of cold Chinese patent medicines is about to undergo major changes
.
.
Statistics show that the current sales of physical pharmacies in Chinese cities have exceeded 10 billion yuan
.
With the continuous expansion of the market, many pharmaceutical companies have also begun to innovate in traditional Chinese medicine for colds
.
Among them, it is worth mentioning that in the field of Chinese patent medicines for colds recently, the approval of Class 1 innovative drugs has been launched
.
On November 15, Kangyuan Pharmaceutical issued an announcement stating that the company’s Yinqiao Qingre Tablets were approved by the State Food and Drug Administration to be used for the treatment of exogenous wind-heat common colds
.
Public information shows that the prescription of Yinqiao Qingre Tablets is based on the famous prescription "Yinqiao Baidu Decoction" of febrile disease by Professor Wang Yongyan, an academician of the Chinese Academy of Engineering.
, Published to relieve muscle, and has the therapeutic effects of clearing lung heat, relieving throat and pain, purging fire and detoxification, relieving cough and resolving phlegm
.
In addition, it is understood that Kangyuan Pharmaceutical’s Yinqiao Qingre Tablets are not only the first category 1.
1 Chinese medicine innovative drug approved for marketing since the implementation of the new Chinese medicine registration classification on July 1, 2020, but also the approval of Jinhua Qinggan Granules in 2016.
Later, in the past five years, it was the first innovative Chinese medicine for colds to be approved for marketing
.
In this regard, the industry believes that the listing of the drug will have an important impact on the market structure of tens of billions of cold Chinese patent medicines, and will further intensify the competition of pharmaceutical companies in this market
.
It is understood that the competition in the cold medicine market of Zhongcheng has been fierce
.
For example, China Resources Sanjiu, Yiling Pharmaceutical, Harbin Medicine Sanjing Pharmaceutical, Henan Tailong Pharmaceutical, Guangzhou Xiangxue Pharmaceutical, etc.
have been increasing their market share in the cold medicine market in recent years
.
Among them, it is worth noting that from the perspective of the market pattern of Chinese patent medicine cold medicines in Chinese urban retail pharmacies in 2020, among the top 20 manufacturers of Chinese patent medicine cold medicines, the position of the “big brother” of China Resources Sanjiu Medicine has been very stable.
It is expected that The market share accounted for 20.
83%
.
The analysis believes that the reason for this phenomenon is mainly due to the rich product line of China Resources Sanjiu Cold and Fever.
Related varieties such as Sanjiu Chinese Medicine Formula Granules, 999 Ganmaoling, 999 Banlangen Granules, 999 Ganmao Qingre Granules, 999 Children’s Cold Medicine and other market demand The amount is also relatively large
.
In addition to China Resources Sanjiu, Shijiazhuang Yiling Pharmaceutical's share in the cold medicine market has also increased significantly in recent years
.
Especially when the epidemic was raging in the first half of 2020, the National Health Commission included Lianhua Qingwen Capsules into the diagnosis and treatment plan.
For a time, Lianhua Qingwen Capsules were swept away in major online and offline pharmacies
.
As a result, the sales volume of Lianhua Qingwen Capsules will greatly increase in 2020.
In the first half of 2020, Lianhua Qingwen accounted for 53% of CR5 cold medicines, and 37.
94% of the overall market of Chinese patent cold medicines
.
It is worth noting that, in addition to a large number of cold Chinese patent medicines that are currently on the market, there are two other cold Chinese patent medicines that are under review, including Shenzhen Sanshun Pharmaceutical’s Caohong Capsules and Tasly’s Xiao Chaihu Decoction Drops.
Pill
.
In this regard, the industry predicts that under the background of the emergence of new drugs, the market for tens of billions of cold Chinese patent medicines is about to undergo major changes
.
